Table 1 Demographics and baseline parameters
From: Specific inhibition of bile acid transport alters plasma lipids and GLP-1
A. Dyslipidemia study | ||||
|---|---|---|---|---|
Placebo (N = 12) | Elobixibat 2.5 mg (N = 12) | Elobixibat 5 mg (N = 12) | ||
Female | n (%) | 8 (66.7) | 7 (58.3) | 6 (50.0) |
Caucasian | n (%) | 12 (100.0) | 12 (100.0) | 12 (100.0) |
Age (years) | Mean (SD) | 64.4 (10.1) | 60.9 (13.2) | 62.7 (11.4) |
Weight (kg) | Mean (SD) | 76.2 (16.3) | 78.1 (16.4) | 76.6 (12.8) |
BMI (kg/m2) | Median | 24.8 | 26.3 | 26.4 |
LDL-Cholesterol (mmol/L) | Mean (SD) | 4.29 (0.71) | 4.61 (0.63) | 4,78 (0.65) |
Cholesterol (mmol/L) | Mean (SD) | 6.38 (0.75) | 6.44 (0.57) | 6.57 (0.72) |
HDL-Cholesterol (mmol/L) | Mean (SD) | 1.53 (0.49) | 1.34 (0.43) | 1.23 (0.30) |
LDL/HDL-Cholesterol (mmol/L) | Mean (SD) | 3.00 (0.92) | 3.77 (1.60) | 4.32 (1.73) |
B. The CC study | ||||
Placebo (N = 13) | Elobixibat 15 mg (N = 12) | Elobixibat 20 mg (N = 11) | ||
Female | n (%) | 13 (100.0) | 12 (100.0) | 11 (100.0) |
Caucasian | n (%) | 11 (92.3) | 12 (100.0) | 12 (100.0) |
Age (years) | Mean (SD) | 47.2 (9.30) | 38.3 (8.18) | 46.1 (6.36) |
Weight (kg) | Mean (SD) | 70.2 (9.7) | 72.9 (15.5) | 75.0 (17.0) |
BMI (kg/m2) | Median | 25.9 | 24.8 | 26.0 |
GLP-1 (pmol/L) | Mean (SD) | 18.45a (8.63) | 15.08 (5.38) | 14.67b (5.92) |